Weight regain after stopping GLP-1 receptor agonists—including orforglipron (Foundayo)—is a well-documented phenomenon because obesity is generally considered a chronic, progressive condition. The Reality of Weight RegainWhen you stop taking these medications, you are essentially removing the phy